Tag: GlobeNewswire

Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026

Initial clinical data expected in the second half of 2027

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) —  Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CR-002, a topoisomerase inhibitor antibody drug-conjugate (ADC) targeting programmed cell death ligand 1 (PD-L1), being developed for the treatment of advanced solid tumors.

“FDA clearance of the CR-002 IND is an important milestone for Crescent and is the third distinct program in our portfolio to enter the clinic,” said Ellie Im, M.D., chief medical officer of Crescent. “The strong scientific rationale and encouraging preclinical profile of CR-002 underscores its promise in addressing a range of solid tumors. We look forward to initiating the APOLLO trial this quarter and working with global investigators to generate important clinical insights and advance our mission of bringing new treatment options to patients living with difficult-to-treat cancers.”

The Phase 1/2 APOLLO global clinical trial plans to enroll patients in the United States, Europe and Asia Pacific with advanced solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and various gastrointestinal and gynecological tumors. The study’s dose escalation and tumor-specific backfill cohorts are expected to enroll approximately 200 participants with the opportunity for additional participants in expansion cohorts. Crescent anticipates reporting initial clinical data from the APOLLO trial in the second half of 2027, including safety, pharmacokinetic and preliminary antitumor activity in multiple tumor types.

About CR-002
CR-002, internally developed in collaboration with Paragon Therapeutics, is a topoisomerase inhibitor ADC directed to PD-L1, a validated target known to have high expression in multiple solid tumors and comparatively limited expression in healthy tissue. CR-002 incorporates a PD-L1 antibody selected for high internalization to facilitate payload release in target cells and a linker designed for intracellular cleavage and high stability in circulation, an approach intended to concentrate payload delivery in tumor tissue. APOLLO, a global Phase 1/2 trial of CR-002 in patients with solid tumors, is anticipated to commence in the fourth quarter of 2026. Crescent also plans to evaluate CR-002 in combination with CR-001, its PD-1 x VEGF bispecific antibody, as part of its efforts to evaluate synergistic ADC and immuno-oncology combinations.

About Crescent Biopharma 
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Forward-Looking Statements 
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Crescent’s expectations, beliefs, or strategies regarding the future of its pipeline and business including, without limitation: the initiation, design, timing, and success of the Phase 1/2 global APOLLO trial; the potential for CR-002 to treat a range of solid tumors; and anticipated timing of reporting proof-of concept data from the APOLLO trial. Forward-looking statements generally relate to future events or future financial or operating performance. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects and involve a number of risks, uncertainties or other assumptions that may cause actual performance to be materially different from those expressed or implied by these forward-looking statements. Risks and uncertainties include, but are not limited to: the expected benefits of, and opportunities related to, the strategic partnership between Crescent and Kelun-Biotech may not be realized or may take longer to realize than anticipated; Crescent’s limited operating history, including with respect to clinical trials; Crescent’s historical losses and any future ability to generate revenue; Crescent’s ability to raise capital to support its business plans; risks associated with clinical development and regulatory approval; risks related to Crescent’s intellectual property; Crescent’s reliance on third parties, including to help develop its product candidates, run its clinical trials, and manufacture its product candidates; significant disruptions of information technology systems or breaches of data security, litigation and regulatory risks; risks related to the current macroeconomic environment, including fluctuating interest rates, barriers to trade, changes to fiscal and monetary policy or government budget dynamics, geopolitical factors, including the ongoing conflicts in Iran and between Russia and Ukraine and the responses thereto, and supply chain disruptions, as well as those factors more fully described in Crescent’s most recent filings with the Securities and Exchange Commission (including its Quarterly Report on Form 10-Q), and Crescent’s other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Crescent’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, Crescent does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements.

Contacts

Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

– In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versus 40% in the placebo arm (p=0.0248); HS troponin I, a blood marker of heart muscle injury, declined more with BBP-418 than placebo (LS mean difference -17.8 ng/L; 95% CI: -35.1 to -0.5; p=0.0443)

– 54% of BBP-418-treated individuals had stable or improved LVEF at Month 12 versus 25% in the placebo arm (p=0.0262)

– In data presented separately, BBP-418 treatment of LGMD2I/R9 in FORTIFY increased mean glycosylated αDG by Month 3 to the levels of asymptomatic heterozygous FKRP carriers, who do not exhibit disease; this result was sustained through Month 12

– Taken together, these findings support the potential of BBP-418 to act as a disease modifying therapy by addressing the condition at its source

– BBP-418 is under FDA Priority Review with a PDUFA target action date of November 27, 2026

PALO ALTO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today presented new exploratory cardiac data from the 12-month interim analysis of FORTIFY, the Phase 3 clinical trial of oral BBP-418 in individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related). The data were presented in an oral presentation at the 31st annual Congress of the World Muscle Society in Hiroshima, Japan by Volker Straub, M.D., Ph.D. of Newcastle University, UK.

“Cardiac involvement is a major driver of morbidity and mortality in LGMD2I/R9, which is why it remains one of the greatest concerns for people living with the condition, families and treating physicians. Historically, we have been able to monitor the heart and manage complications, but we have not been able to address the underlying cause of the disease,” said Dr. Straub. “What stands out in this analysis is how consistent it is: high-sensitivity troponin I fell and, in those who entered the study with elevated levels, it normalized; ejection fraction stabilized; and this happened alongside walking farther and breathing better. It’s encouraging to see that the therapeutic approach seems to work across the whole muscular system, including the heart.”

Cardiomyopathy affects approximately 30% of individuals with LGMD2I/R9 and approximately 60% of those with other FKRP genotypes, and is progressive, with an annual loss of approximately 0.4% of left ventricular ejection fraction (LVEF). In FORTIFY, 22.9% of participants (25/109) had elevated high-sensitivity (HS) troponin I at baseline and 17.1% (18/105) had an LVEF below 50%. Exploratory cardiac findings at Month 12 showed:

• HS troponin I is a blood test used to detect injury to heart muscle. 100% of the participants treated with BBP-418 returned to the normal range for HS troponin l by Month 12 versus 40% in the placebo arm (p=0.0248); HS troponin I declined more with BBP-418 than placebo (LS mean difference -17.8 ng/L; 95% CI: -35.1 to -0.5; p=0.0443)
• At Month 12, 54% of participants treated with BBP-418 had stable or improved LVEF, a measurement of how much blood the heart’s main chamber pushes out with each beat, compared with 25% of those on placebo (p=0.0262)
• Both HS troponin I and LVEF will continue to be monitored in the ongoing FORTIFY study

A consistent pattern across the FORTIFY interim analysis is the proportion of treated individuals reaching normal or near-normal levels on markers of the disease e.g., 38% of patients whose CK reached normal levels. In addition to the HS troponin I finding, in which 100% of evaluable BBP-418-treated participants with elevated levels at baseline returned to the normal range by Month 12, separate data presented at WMS 2026 by Anne Katrine Kjemsø Jensen, a medical student in the laboratory of John Vissing M.D., D.M.Sci., Copenhagen Neuromuscular Center of Rigshospitalet, DK, quantified αDG glycosylation in 34 asymptomatic heterozygous FKRP carriers. Results showed:

• Asymptomatic carriers showed significantly reduced glycosylation versus healthy controls, thereby establishing a reference point for the level associated with normal muscle function (34% of control)
• In FORTIFY, BBP-418 treatment increased mean glycosylated αDG above carrier levels by Month 12, suggesting that BBP-418 can restore glycosylated αDG to asymptomatic levels
• While many therapies in progressive neuromuscular disease aim to slow decline, BBP-418 was developed to target LGMD2I/R9 at its source, and the pattern of biomarker normalization observed to date, alongside functional improvement from baseline rather than stabilization, is consistent with the potential for BBP-418 to be a disease modifying therapy

In the Phase 3 FORTIFY trial, BBP-418 met all primary and secondary endpoints at the pre-specified 12-month interim analysis, showing treated individuals improving while placebo recipients declined across every key measure. These results were presented as a late-breaking oral presentation at the 2026 MDA Clinical and Scientific Conference, which are available here.

BridgeBio believes BBP-418 is positioned to become the first and only approved therapy for individuals living with LGMD2I/R9, addressing a significant unmet need in this disease and potentially representing the first approval of a therapy for any form of LGMD. Approximately 7,000 individuals currently live with LGMD2I/R9 and other addressable α-dystroglycanopathies in the U.S. and Europe. BBP-418 is under FDA Priority Review with a PDUFA target action date of November 27, 2026. The Company is also engaging regulatory agencies to identify an expedited path to approval for BBP-418 in Europe.

BBP-418 has previously received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA and Orphan Drug Designation from the European Medicines Agency (EMA). BBP-418 received Priority Review from the FDA, highlighting the potential for BBP-418 to address unmet need in LGMD2I/R9. Consistent with Rare Pediatric Designation from the FDA, if BBP-418 is approved, BridgeBio may qualify for a Priority Review Voucher. The Company intends to initiate clinical studies of BBP-418 in LGMD2I/R9 for individuals less than 12 years of age in the first half of 2027 and in LGMD2M/R13 and LGMD2U/R20 in the near future.

About Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
LGMD2I/R9 is a monogenic autosomal recessive disease caused by partial loss of function mutations in the fukutin-related protein (FKRP) gene, and FKRP mutations impair glycosylation of alpha-dystroglycan (αDG), a protein associated with stabilizing muscle cells. Clinical manifestations typically present as a skeletal myopathy affecting the lower and then upper limbs, which is commonly later accompanied by pulmonary muscle and cardiac muscle involvement. Individuals who harbor a homozygous L276I genotype typically develop disease manifestations during late childhood with progression to loss of independent ambulation (25%), assisted ventilation (10%), and cardiomyopathy (30%) in adulthood. Cardiomyopathy is progressive, with an annual loss of 0.4% of left ventricular ejection fraction (LVEF). Individuals with other FKRP genotypes typically have an earlier childhood onset with a more severe clinical course, rapid loss of mobility by 20 years of age, more frequent cardiac involvement (60%), and eventual pulmonary decline by 30 years of age in nearly all cases.

About BBP-418
BBP-418 is an investigational oral glycosylation substrate therapy with potential to be the first and only therapy for LGMD2I/R9. BBP-418 is designed to saturate the partially functional FKRP enzyme with substrate thereby enhancing residual FKRP function and restoring glycosylation of αDG. Through restoration of αDG glycosylation, BBP-418 may stabilize or improve muscle function, including gross motor, ambulatory, and cardiopulmonary function.

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of data regarding BBP-418, including the potential for BBP-418 to act as a disease-modifying therapy for LGMD2I/R9, restore or normalize disease biomarkers, and stabilize or improve cardiac, gross motor, ambulatory and pulmonary function; the potential for BBP-418 to become the first and only approved therapy for individuals living with LGMD2I/R9 and potentially the first approved therapy for any form of LGMD; the timing and likelihood of potential regulatory approval and commercialization of BBP-418, including the PDUFA target action date of November 27, 2026; BridgeBio’s interactions with regulatory authorities regarding a potential expedited path to approval for BBP-418 in Europe; BridgeBio’s potential eligibility to receive a Priority Review Voucher if BBP-418 is approved; the continued evaluation of cardiac and other clinical measures in the ongoing FORTIFY study; and BridgeBio’s plans to initiate additional clinical studies of BBP-418, including in individuals with LGMD2I/R9 less than 12 years of age and in individuals with LGMD2M/R13 and LGMD2U/R20. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s preclinical studies and clinical trials not being indicative of final data; the exploratory and non-alpha-controlled nature of certain analyses described in this press release and the small sample sizes on which certain of those analyses are based; that observed biomarker changes, including normalization of HS troponin I, glycosylated αDG or other disease markers, may not be replicated in additional analyses or studies or predict or translate into long-term clinical benefit, sustained improvement in cardiac or other muscle function, or prevention of disease progression; that BBP-418 may not demonstrate the anticipated efficacy, safety, therapeutic benefit or disease-modifying potential in ongoing or future clinical studies; that the design, enrollment, conduct, timing and success of ongoing and planned clinical trials may differ from current expectations; that the FDA or other regulatory authorities may not approve BBP-418 on the anticipated timeline or at all, may not agree with BridgeBio’s regulatory approval strategies, clinical trial designs, conduct or methodologies, or the sufficiency of data submitted, or may require additional data, studies or other information; that BBP-418 may not become the first and only approved therapy for LGMD2I/R9 or the first approved therapy for any form of LGMD; that BridgeBio may not identify or obtain an expedited path to approval for BBP-418 in Europe; that BridgeBio may not qualify for or receive a Priority Review Voucher; that plans to initiate additional clinical studies, including studies in individuals less than 12 years of age or in other forms of LGMD, may be delayed, modified or may not occur as expected; the potential size of the target patient populations BBP-418 is designed to treat not being as large as anticipated; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com  
(650) 789-8220

BridgeBio Investor Contact
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Canadian Goldfields Discovery Corp. (TSX-V: CGM, OTCQB: CGMXF) (“Canadian Goldfields” or the “Company”) is pleased to announce the completion of soil geochemistry and upcoming commencement of a property-wide airborne magnetic survey at its 6,366-hectare Miminiska Gold Project in northwestern Ontario. The programs are intended to identify new exploration targets, support future drilling and further define regional controls on gold mineralization.

Construction of a winterized exploration camp is underway at Miminiska to support continued field activities and future drilling. Approximately 40% of current site staff are members of the Eabametoong First Nation (“EFN”).

Ian Dasti, Vice-President of Exploration, P.Geo., commented: “We have a 14-kilometre prospective trend at Miminiska with historical drilling concentrated at the Miminiska and Frond Zones, leaving more than 12 kilometres of strike largely untested. Our current programs are designed to systematically evaluate this broader opportunity. By integrating soil geochemistry with property-wide airborne magnetics and our existing geological data, we aim to improve our understanding of the controls on gold mineralization and advance growth-focused target generation for future drilling.”

Highlights

• Growth-Focused Target Generation: Soil geochemistry and upcoming property-wide airborne magnetics will be integrated with geological data to develop new exploration targets for future drilling.
• Systematic Geochemical Coverage: 329 soil samples collected between Frond and Wottam Lake on a 50 m × 100 m grid, with assays pending.
• Property-Wide Airborne Geophysics: HeliGT airborne magnetic survey expected to commence before the end of October to further define geological and structural controls on gold mineralization.
• Winter Exploration Infrastructure: Winterized exploration camp under construction to support continued field activities and future drilling.
• Strong Local Participation: 40% of current Miminiska site staff are members of Eabametoong First Nation.

Soil Geochemistry

The Company completed 329 soil samples, including quality-control samples, along 39 Ha of the prospective trend between Frond and Wottam Lake on a 50-metre by 100-metre grid. The program is designed to:

• Initiate systematic geochemical coverage across prospective ground between Frond and Wottam Lake;
• Identify gold and trace-element geochemical patterns for follow-up exploration; and
• Support target generation through integration with geological mapping, historical data and airborne geophysics.

Samples have been submitted to Activation Laboratories Ltd. (“Actlabs”) for gold and trace-element analysis, with results anticipated before the end of October 2026.

Airborne Geophysics

The Company is preparing to commence a HeliGT airborne magnetic survey across the entire Miminiska Property using SHA Geophysics. The survey is designed to:

• Provide high-resolution magnetic coverage across the 6,366-hectare Project;
• Further define geological and structural controls on gold mineralization; and
• Support target generation through integration with soil geochemistry, geological mapping and historical data.

The survey is expected to commence before the end of October 2026.

Winter Exploration Camp

Construction of the Company’s winterized exploration camp at Miminiska is underway to support continued field activities and future drilling.

Approximately 40% of current Miminiska site staff are members of Eabametoong First Nation (“EFN”). Canadian Goldfields continues to work collaboratively with EFN as exploration activities at Miminiska advance.

Selected Historical Drill Results

Approximately 28,000 metres of historical drilling has been completed at Miminiska, concentrated principally at the Miminiska and Frond Zones. Selected historical drill results are presented below. These results are historical in nature, have not been independently verified by the Qualified Person and are reported as core lengths that do not necessarily represent true widths.

Area	Hole ID	Azimuth (°)	Dip (°)	From (m)	To (m)	Interval (m)	Au (g/t)
Miminiska	0603-08	358.4	-70	51.94	72.78	20.84	5.75
Miminiska	88C-10	315	-50	65.38	69.34	3.96	12.69
Miminiska	0603-18	358.1	-50	120.57	131.75	11.18	4.49
	including			120.57	124.30	3.73	7.29
Miminiska	0604-32	358	-66	235.78	241.10	5.32	13.95
Frond	87-13	144	-50	125.79	127.10	1.31	14.74
Frond	87-10	144	-45	67.79	69.04	1.25	7.53
Frond	87-14	144	-65	61.66	62.00	0.34	37.02
Frond	87-15	144	-70	92.20	93.15	0.95	11.32

NI 43-101 Technical Report on the Miminiska Property, Northern Ontario, Canada, prepared by APEX Geoscience Ltd. for Canadian Goldfields, authored by Qualified Persons Edward Parker, B.Sc., P.Geo., and Eliza D. Verigeanu, M.Sc., P.Geo. Frond Zone results adapted from Neal & Miller Report, 1987. Effective date of December 1, 2025.

About Canadian Goldfields Discovery Corp.

Canadian Goldfields Discovery Corp. is a Canadian mineral exploration company focused on advancing district-scale gold opportunities in Ontario, Canada. The Company’s portfolio includes the flagship Miminiska Gold Project in northwestern Ontario and the Swayze Central Gold Property located within the prospective Swayze Greenstone Belt near Timmins.

Miminiska hosts a gold-rich banded iron formation (“BIF”) system with multiple high-grade intercepts drilled across the Miminiska and Frond Zones and more than 14 km of underexplored strike extent. Supported by approximately 28,000 m of historical drilling, the project demonstrates significant scale potential with mineralization remaining open along strike and at depth. The Swayze Central Gold Property complements the Company’s portfolio with historical high-grade gold occurrences and additional district-scale exploration upside in one of Canada’s most established mining regions.

Canadian Goldfields is led by a lean and execution-focused leadership team committed to disciplined exploration, systematic discovery and long-term value creation through the advancement of high-quality gold assets in tier-one mining jurisdictions.

On behalf of the Company,
John G. Booth, Chief Executive Officer and Director

Additional Information
Harp Gosal | Director of Capital Markets & Communications
Canadian Goldfields Discovery Corp.
Phone: (604) 218-1142
Email: hgosal@canadiangoldfields.com

Qualified Persons and Technical Disclosure

The scientific and technical information contained in this news release has been reviewed and approved by Ian Raymond Dasti, P.Geo, Vice-President of Exploration of Canadian Goldfields Discovery Corp., and a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI-43101”).

Mr. Dasti has reviewed the technical information disclosed in this news release and has approved its dissemination. The information presented herein relates to planned exploration activities at the Company’s Miminiska Gold Project, including the design and objectives of the geochemical soil sampling program.

Historical exploration information referenced in this news release has been compiled from publicly available sources and historical reports. A Qualified Person has not completed sufficient work to independently verify all historical information, and the Company is not treating such information as current mineral resources or mineral reserves as defined by NI 43-101. Historical results, mineral occurrences, and exploration data should not be relied upon as indicative of future exploration results.

The Company considers historical exploration information to be relevant for the purpose of guiding future exploration programs; however, readers are cautioned that such information may not be representative of actual mineralization or exploration potential on the Property.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by many material factors, many of which are beyond their respective control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the Company’s planned exploration program for the Miminiska Gold Property is subject to change. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company does not undertake to publicly update or revise forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

NEW YORK and SEOUL, South Korea, Oct. 05, 2026 (GLOBE NEWSWIRE) — Nexus Advanced Technologies Inc. (Nasdaq: NXAT), formerly K Wave Media Ltd. (the “Company”), today announced that it has entered into an ATM Consent, Note Repayment and Warrant Exchange Agreement (the Note and Warrant Restructuring Agreement”), effective as of October 2, 2026, with Anson Investments Master Fund L.P. and Anson East Master Fund L.P. (collectively, the “Anson Funds”).

The Note and Warrant Restructuring Agreement is intended to simplify the Company’s capital structure and support future financing as management evaluates potential acquisitions, mergers and other strategic transactions across the AI ecosystem and advanced technologies. There can be no assurance that any transaction will be pursued or completed.

Under the Note and Warrant Restructuring Agreement, i) full payment of $2.5 million will make the remaining note convertible solely at a fixed price equal to the average daily VWAP for the three trading days immediately preceding full payment, with its anti-dilution, price-reset and similar adjustment provisions ceasing to apply. ii) Anson may, at its discretion, exchange warrants covering 8,310,250 ordinary shares for an aggregate of 4.5 million ordinary shares, subject to ownership limits and specified adjustments; delivery of the corresponding exchange shares cancels the exchanged warrants, and completion of the full exchange eliminates their anti-dilution and price-adjustment provisions. The cashless exchange provides no cash proceeds to the Company and will dilute existing shareholders. iii) Anson has also consented to an ATM offering during the agreed consent period at a minimum public offering price of $2.00 per ordinary share. Existing adjustment provisions continue until the applicable payment or exchange milestone is completed, and other note terms and specified financing restrictions, participation rights, repayment rights and security arrangements remain in effect except as expressly amended or waived.

“Our objective is to make our capital structure more predictable as we pursue future financing and evaluate strategic acquisitions and other transactions,” said Myungjong Kim, Co-Chief Executive. “Completing the agreed payment and other requirements per the agreement will eliminate variable conversion pricing and anti-dilution adjustments from the remaining note, while completing the warrant exchange will retire the exchanged warrants and their adjustment provisions.”

The Company will furnish the Note and Warrant Restructuring Agreement and this release to the Securities and Exchange Commission on Form 6-K. Investors should review the Note and Warrant Restructuring Agreement for the complete terms, conditions and continuing obligations.

About Nexus Advanced Technologies
Nexus Advanced Technologies Inc. (Nasdaq: NXAT) pursues strategic investments, acquisitions and partnerships across AI infrastructure and advanced technologies, including data centers, AI compute and GPU infrastructure.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding the ATM offering, the application of ATM proceeds, the repayment and conversion of the Note, the exchange of warrants for ordinary shares, the Company’s capital structure and financial flexibility, and the Company’s evaluation of potential strategic transactions.

These forward-looking statements are based on management’s current expectations, assumptions and estimates and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including: general market and economic conditions; the Company’s ability to conduct the ATM offering on anticipated terms or at all; the Company’s ability to make the required payments under the Agreement; the timing and amount of any warrant exchanges; the Company’s ability to identify, negotiate and consummate any strategic transaction; and the risks and uncertainties described in the Company’s most recent Annual Report on Form 20-F and subsequent filings with the U.S. Securities and Exchange Commission.

The Company can provide no assurance that it will enter into or consummate any strategic transaction, or that any such transaction, if completed, will achieve its intended benefits.

All forward-looking statements speak only as of the date of this press release and are qualified in their entirety by reference to the factors discussed in the Company’s filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact:
Investor Relations: info@kwavemedia.com
Public Relations: info@redroosterpr.com

Transaction supports ownership of key cultivation and production infrastructure in Two Core Markets

MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform, today announced that VIREO PROPERTY HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), VIREO PROPERTY HOLDINGS NEW YORK, LLC, a Delaware limited liability company (“Holdings NY”), VIREO PROPERTY HOLDINGS FLORIDA, LLC, a Delaware limited liability company (“Holdings FL”), 256 COUNTY ROUTE 117 PERTH LLC, a Delaware limited liability company (“NY PropCo”), and 160 COMFORT ROAD, LLC, a Delaware limited liability company (“FL PropCo”, and together with Holdings, Holdings NY, Holdings FL and NY PropCo, collectively, the “Borrower”), have entered into a US$60 million real estate financing (the “Loan”) with a U.S. commercial bank and institutional lender, related to the cannabis cultivation and production facilities located in Johnstown, New York and Palatka, Florida (collectively, the “Properties”). Approximately US$49 million of the financing proceeds are being used to refinance existing senior debt that was entered into in connection with the previously announced option to purchase the Johnstown facility and approximately US$11 million of the financing proceeds are being used to finance the acquisition of the Palatka facility. The Palatka facility is a significant cultivation and production asset supporting the Company’s Green Dragon operations and is an important component of Vireo’s strategy to build scale and strengthen its vertically integrated platform in Florida. The Palatka facility was previously leased from Rainbow Palatka FL LLC (“Rainbow”). In connection with the acquisition of the Palatka facility, the existing lease with Rainbow will be terminated and a new lease with Green Dragon Florida LLC, an affiliate of Vireo, will be executed. The US$60 million loan bears interest at 8.5% per annum and matures on April 2, 2034. The Loan is secured by a first-priority mortgage on the Properties, a first priority pledge of membership interests by each of Vireo Health Inc., a wholly owned subsidiary of Vireo, Holdings, Holdings NY and Holdings FL in their respective wholly owned subsidiaries comprising Borrower, a security interest in substantially all personal property of the Borrowers and other loan parties and is subject to customary terms and conditions.

“This $60 million credit facility is an important milestone for Vireo and directly supports our strategic growth plans,” said Tyson Macdonald, Chief Financial Officer of Vireo Growth. “The facility carries an 8.5% interest rate, among the most attractive rates in the cannabis sector, and reflects the strength of our business and continued access to institutional capital as we execute on our growth strategy. We look forward to working with the lender as a long-term banking partner for our future capital needs.”

Additional information regarding the financing and its material terms and conditions will be included in the Company’s regulatory filings.

About Vireo Growth Inc.

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) is a leading vertically integrated cannabis company building a broad platform across cannabis and adjacent agricultural markets. The Company operates cultivation, manufacturing, retail dispensaries, home delivery, distribution, and agricultural supply businesses across the United States, creating exposure to both cannabis and complementary adjacent markets. With operations in 10 states and more than 170 dispensaries nationwide, Vireo combines disciplined capital allocation, strategic acquisitions, and local market execution to scale its platform and drive long-term shareholder value. The Company is focused on expanding market share and strengthening its portfolio of consumer brands and services, while supporting the customers, employees, shareholders, and communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Forward-Looking Information

This press release contains “forward-looking information” or “forward-looking statements” within the meaning of applicable United States and Canadian securities legislation (referred to herein as “forward-looking information”). Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” and variations of such words and phrases, or any statements or clauses containing verbs in any future tense and includes statements regarding the expected benefits of the ownership of the Properties; and the Company’s expectations regarding its ability to service the Loan. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release and are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the Company’s ability to service the Loan; risks that the anticipated benefits of the ownership of the Properties may not be realized; the Company’s ability to maintain relationships with suppliers, customers, employees and other third parties in connection with the Properties; the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions; risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in its various markets; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on EDGAR with the U.S. Securities and Exchange Commission at www.sec.gov and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.com.

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

For Vireo, contact:

Lynn Ricci
Director Investor Relations & Corporate Communications
investor@vireogrowth.com
781-956-7052

MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) is pleased to announce it has completed a first gold pour at its Galam pilot plant in Senegal.

Highlights

• First gold doré pour achieved on September 30, 2026 with gold-silver cement from the Merrill-Crowe circuit.
• Plant run time and gold recovery are increasing steadily since completion of commissioning.
• Next step is to ramp up production to nameplate capacity.

Daniel Misiano, President & CEO of Dynacor, commented: “We are delighted to highlight our first gold pour on the continent of Africa, marking our transition into a geographically diversified gold processor. Galam is now the first gold processing plant servicing permitted ASGM in Senegal and poised to deliver strong benefits to stakeholders as we showcase our platform in Africa.

We would like to extend our sincere thanks to the experienced team who drove the construction and commissioning of the Galam modular plant. Their tremendous efforts and commitment to excellence accelerated construction of the plant over a 10-month period and with no lost-time injuries.”

Figure 1: Introducing the Team Behind Dynacor’s First Senegalese Gold Pour

Figure 2: Introducing Dynacor’s First African Bar

About the Galam Plant

Dynacor’s wholly owned Galam subsidiary hosts a 50-tpd modular processing plant that will serve as a test ground for Dynacor’s expansion into Senegal and Africa at large. Galam’s location in Kédougou places it at the heart of the main Artisanal and Small-Scale Gold Mining (ASGM) region in Senegal where some 98% of national ASGM sites and 13/16 government-permitted ASGM corridors are located. If successful, the Galam pilot plant will be a precursor to a 300-tpd commercial processing plant in Senegal.

About Dynacor

Dynacor Group is an ore processing company dedicated to producing gold sourced from artisanal miners. Since its establishment in 1996, Dynacor has pioneered a responsible mineral supply chain with stringent traceability and audit standards for the fast-growing artisanal mining industry. By focusing on formalized miners, the Canadian company offers a win-win approach for governments and miners globally. Dynacor operates the Veta Dorada plant and owns a gold exploration property in Peru. The company is expanding to West Africa and within Latin America.

The premium paid by luxury jewellers for Dynacor’s PX Impact® gold goes to Fidamar Foundation, an NGO that mainly invests in health and education projects for artisanal mining communities in Peru. Visit www.dynacor.com for more information.

Forward-Looking Information

Certain statements in the preceding may constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Dynacor, or industry results, to be materially different from any future result, performance or achievement expressed or implied by such forward-looking statements. These statements reflect management’s current expectations regarding future events and operating performance as of the date of this news release.

Contact:

For more information, please contact:

Ruth Hanna
Director, Investor Relations
T: 514-393-9000 #236

E: investors@dynacor.com
Website: https://dynacor.com

Renmark Financial Communications Inc.
Bettina Filippone
T: (416) 644-2020 or (212) 812-7680
E: bfilippone@renmarkfinancial.com  
Website: www.renmarkfinancial.com

Photos accompanying this announcement is available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/f0b94e1d-8a6a-47ea-8e0a-81eca3b896c2

https://www.globenewswire.com/NewsRoom/AttachmentNg/96a571b0-6185-4986-8bf7-d5abb286ea91

Drilling will test extensions at depth and along strike of a historically productive uranium system

Vancouver, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Terra Clean Energy Corp. (“Terra” or the “Company”) (CSE: TCEC; OTCQB: TCEFF; FSE: C9O0) is pleased to announce that it has contracted KB Drilling Co., Inc. of Mound House, Nevada, to conduct the Company’s planned 10,000-foot core drilling campaign at its Marysvale Uranium Mines Project in Utah, United States beginning the first week of November 2026.

The program will evaluate the resource potential surrounding the past-producing Prospector and Freedom uranium mines. The mines are located within Utah’s historic Marysvale Uranium District, which produced approximately 1.33 million pounds of U3O8 at an average grade of approximately 0.22% U3O8. The Prospector and Freedom mines accounted for more than 75% of the district’s historical production.

Terra will be drilling a historically productive and comparatively well-understood epithermal uranium vein system. Historical underground development, drilling records, assay results and geological information provide the Company with an extensive technical foundation from which to target potential extensions of the mineralized veins.

The planned drill program will comprise approximately 10,000 feet of diamond core drilling from five permitted drill pads encompassing 12 drill targets. Drill targets have been developed using historical mine and drilling records including underground engineering reports, drill holes and assays, underground sampling, geological mapping, radiometric survey data all feeding the Company’s extensive three-dimensional geological model.

Testing the Full Potential of a Historic Uranium System

The Marysvale Uranium District hosts structurally controlled, volcanic-hosted epithermal uranium mineralization occurring principally within steeply dipping veins and associated fracture zones.

The Company believes the project offers significant exploration potential because:

• Historical mining was concentrated on accessible portions of the known veins;

• Historical drilling indicates that mineralization continues more than 600 feet below portions of the former underground workings;

• The mineralized structures remain open for testing along strike and at depth;

• Historical drill logs, assay information, geochemical data, underground workings and mine maps have been digitized and incorporated into the Company’s three-dimensional geological model; and

• Modern core drilling, downhole surveying and three-dimensional modelling provide Terra with tools unavailable to the historical operators.

The principal objectives of the program are to:

1. Test the down-dip continuation of mineralized veins beneath the former mine workings;
2. Evaluate strike extensions beyond the historically mined areas;
3. Confirm the location, orientation, width and grade of known mineralized structures;
4. Identify parallel veins and previously unrecognized mineralized structures; and
5. Generate geological and assay information to guide subsequent drilling and resource-evaluation work.

“This is an exciting milestone for Terra – drilling at a former producing uranium operation where the geological controls on mineralization are well understood,” stated Greg Cameron, Chief Executive Officer of Terra Clean Energy. “Historical mining focused on accessible portions of the known veins, while drilling and mine records indicate that the system continues beyond the former workings.”

“We believe there is substantial potential to expand the known mineralized footprint. This 10,000-foot core program will test the veins along strike and at depth, investigate mineralization beneath the historical workings and evaluate parallel structures that may never have been adequately tested. Contracting KB Drilling moves us into the most important phase of the program – putting core in the ground.”

Site preparation crews are scheduled to begin constructing the permitted drill pads and excavating the planned exploration trenches during the final week of September. KB Drilling is scheduled to mobilize to the project and commence core drilling during the final week of October 2026.

The Company’s previously announced private placement and current cash on hand will provide funding for the work program at the Marysvale Uranium Mines Project, including the planned core drilling campaign and initial environmental baseline study.

Gruner, J.W., Fetzer, W.G., and Rapaport, I., 1951, The Uranium Deposits near Marysvale, Piute County, Utah, Economic Geology Vol 46 No 3, pp. 243-251.

Steven, T.A., Cunningham, C. G., Naeser, C.W., and Mehnert, H.H., 1979, Revised stratigraphy and radiometric ages of volcanic rocks in the Marysvale area, west-central Utah: U.S. Geological Survey Bulletin 1469, 40 p.

*The historical results, production, and interpretation described here in have not been verified and are extracted from US Geological Survey reports. The Company has not completed sufficient work to confirm and validate any of the historical data contained in this news release. The historical work does not meet NI 43-101 standards. The Company considers the historical work a reliable indication of the potential of the Marysvale Uranium Mines Project and the information may be of assistance to readers.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved in accordance with the Canadian regulatory requirements set out in National Instrument 43-101, on behalf of the Company by C. Trevor Perkins, P.Geo., Vice President Exploration for Terra Clean Energy Corp., and a Qualified Person as defined by National Instrument 43-101.

About K B Drilling Co Inc

KB Drilling Co Inc. is Mound House, Nevada based drilling contractor with experience in mineral exploration and diamond core drilling programs for a range of projects across the Western United States.

ABOUT TERRA CLEAN ENERGY CORP.

Terra Clean Energy Corp. is a Canadian-based uranium exploration and development company. The Company is currently developing the South Falcon East uranium project located in the Athabasca Basin region, Saskatchewan, Canada as well as past producing uranium mines in Utah and uranium exploration properties in Wyoming, United States. The Company’s strategy is to find and advance late-stage uranium projects to support growing demand for Nuclear Power and secure domestic mineral supply chains.

Contact Information

Terra Clean Energy Corp.
Greg Cameron, Chief Executive Officer
416-277-6174
 
For further information please visit Terra Clean Energy’s website at www.tcec.energy.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

This news release contains forward-looking information, including statements concerning the mobilization of drilling and site-preparation crews; the timing, scope and objectives of the planned 10,000-foot core drilling campaign; the potential continuity and extensions of uranium mineralization; the possibility of identifying additional mineralized veins and structures; the Company’s interpretation of historical information; and the intended use of financing proceeds. Forward-looking information is based on assumptions considered reasonable by management as of the date of this release and is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated. Exploration results cannot be predicted, and there is no assurance that the program will identify mineralization of economic interest or result in the definition of a mineral resource. Readers are cautioned not to place undue reliance on forward-looking information. The Company undertakes no obligation to update such information except as required by applicable securities laws.

Board previously adopted committee charters written to Nasdaq listing standards, strengthening oversight of financial reporting, executive pay and board quality as the Company pursues its Nasdaq application

RENO, Nev., Oct. 05, 2026 (GLOBE NEWSWIRE) — Globaltech Corporation (OTCQB: GLTK) (“Globaltech” or the “Company”), a U.S.-based technology platform company enabling growth in AI, data and frontier technologies, today confirmed the composition of its three standing Board committees – the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee – and the adoption of a charter for each committee.

The charters and committee appointments were approved by unanimous written consent of the Board of Directors effective January 7, 2026, together with the Company’s Code of Ethics and Clawback Policy. The charters are written according to the independence and composition standards of the Nasdaq Capital Market.

Each committee is comprised of directors the Board has determined to be independent in accordance with Nasdaq’s rules which generally require that they are not part of the Company’s management and have no financial relationship with the Company beyond their role as directors.

The Board is chaired by James A. Gibbons, who served as the 28th Governor of Nevada from 2007 to 2011 and before that represented Nevada for five terms in the U.S. House of Representatives. An attorney by training, Governor Gibbons is also a former U.S. Air Force and Nevada Air National Guard pilot.

Committee membership

• Audit Committee: Mehdi Al Abduwani (Chair), James A. Gibbons, and David J. Fox. The Board has designated Mehdi Al Abduwani as the Committee’s audit committee financial expert.
• Compensation Committee: Charles J. Bartolotta (Chair), Mehdi Al Abduwani, and Shahid A. Khan.
• Nominating and Corporate Governance Committee: James A. Gibbons (Chair), David J. Fox, and Shahid A. Khan.

What each committee does

The Audit Committee oversees the preparation of the Company’s financial statements. It hires and supervises the independent auditor, reviews every quarterly and annual report before it is filed, monitors internal controls, approves any transaction between the Company and an insider, and maintains a confidential channel for employees to report concerns. It also oversees the Company’s cybersecurity and data-privacy risks.

The Compensation Committee establishes the pay of the Chief Executive Officer and other executive officers and recommends director compensation to the Board. It ties executive pay to performance, administers the Company’s equity plans, and oversees the Company’s clawback policy, under which certain incentive pay can be recovered if financial results are later restated. No executive takes part in decisions about his or her own pay.

The Nominating and Corporate Governance Committee decides who is nominated to serve on the Board. It sets the criteria for directors, leads the search for candidates, evaluates the performance of sitting directors each year, and keeps the Company’s governance guidelines current. Shareholders may recommend director candidates in writing to the Company Secretary.

What this means for our shareholders

In plain terms, the people who oversee the preparation of the Company’s financials, set executive pay and choose directors are now overseen by independent directors who have a fiduciary duty to the shareholders. This is the structure investors expect of a company listed on a national exchange, considered best practices and is typically required for a Nasdaq listing.

“A company earns the trust of the market one structure at a time,” said Dan Green, Chief Executive Officer of Globaltech. “Independent committees overseeing financial reporting, executive pay and board composition are the foundation of that trust. We have put them in place ahead of our planned move to a national exchange, because our shareholders should not have to wait for a listing to get that level of oversight.”

“Good governance is not a box to check. It is how a board earns the right to be trusted with other people’s money,” said James A. Gibbons, Chairman of the Board. “These committees put independent directors in charge of the questions shareholders care about most. Mehdi, Charles and I take those responsibilities seriously.”

Globaltech’s common stock was approved for quotation on the OTCQB Venture Market on March 26, 2026, and the Company completed a 1-for-3 reverse stock split on August 27, 2026.

The Company has applied to list its common stock shares on the Nasdaq Capital Market, which application is currently under review. Any listing remains subject to Nasdaq’s review, satisfaction of all applicable initial listing standards and other customary conditions, as well as Nasdaq’s discretionary approval to uplist, and there can be no assurance regarding the timing or completion of the up listing.

About Globaltech Corporation

Globaltech Corporation (OTCQB: GLTK) is a technology platform company building and commercializing AI, data and software solutions through its revenue-generating operating businesses. Its telecommunications and retail operations provide infrastructure, customer relationships and real-world environments to develop, test and scale technology platforms spanning financial technology, enterprise software, e-commerce and sports technology. Through its Center of Excellence, Globaltech evaluates, develops and commercializes technology opportunities across the platform.

For more information, please visit www.globaltechcorporation.com.

Company Contact

Dan Green
Chief Executive Officer, Globaltech Corporation
investors@globaltechcorporation.com
Toll Free: (888) 760-7067
USA: (775) 624-4817

Forward-Looking Statements

Forward-looking statements in this release include certain of the matters discussed in this communication which are not statements of historical fact constitute forward-looking statements that involve a number of risks and uncertainties, including statements regarding the Company’s planned uplisting to the Nasdaq Capital Market, its ability to satisfy Nasdaq’s initial listing requirements and obtain listing approval, and other matters. Words such as “strategy,” “expects,” “continues,” “plans,” “anticipates,” “believes,” “would,” “will,” “estimates,” “intends,” “projects,” “goals,” “targets” and other words of similar meaning are intended to identify forward-looking statements but are not the exclusive means of identifying these statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. Important factors that may cause actual results and outcomes to differ materially from those contained in such forward-looking statements include, without limitation: (a) our ability to uplist our common stock to Nasdaq, including the fact that we do not currently meet Nasdaq’s initial listing requirements, may not meet such requirements in the future, may not obtain approval of our application to list our common stock on Nasdaq on a timely basis, if at all, even if we meet all of the required quantitative listing requirements; (b) our strategic plans and treasury management initiatives; (c) risks relating to previously disclosed debt defaults and our ability to extend or refinance such debt, our need for additional capital, the terms of such capital and the potential dilution to stockholders caused thereby, including through the issuance of additional shares of common stock or upon conversion of outstanding convertible notes; (d) changes in consumer preferences, purchasing behavior, competitive conditions, and industry trends; (e) macroeconomic, geopolitical, and financial market conditions, including inflation, interest rates, tariffs, and consumer spending levels; (f) disruptions to sourcing, manufacturing, supply chain, logistics, labor availability, and the cost or availability of raw materials and finished goods; (g) the Company’s ability to successfully manage inventory, respond to changing fashion trends, maintain the strength of its brands, and execute its retail and growth strategies; (h) foreign currency exchange losses, fluctuations and translation risks related to our business in Pakistan and the United Kingdom; (i) the international economic environment, geopolitical developments and unexpected global events, including economic downturns in Pakistan, the United Kingdom and globally, changes in inflation and interest rates, tariffs, increased borrowing costs and potential declines in the availability of funding; (j) the greater political, legal and economic risks associated with operating in emerging markets as compared to more developed markets; (k) the unpredictability of our revenue performance, including because a significant majority of our customers have not entered into long-term fixed contracts with us; (l) our ability to compete in highly competitive markets, which we expect to become increasingly competitive, and our ability to expand our customer base and retain existing customers; (m) our ability to keep pace with technological changes and evolving industry standards; (n) cyber-attacks and other cybersecurity threats that may lead to compromised or inaccessible telecommunications, digital and financial services, leaks or unauthorized processing of confidential information, and the potential loss of customer confidence resulting therefrom; (o) the highly capital-intensive nature of the telecommunications industry and the substantial and ongoing capital expenditures required to operate and grow our business; (p) the terms of our interconnect agreements and our access to third-party-owned infrastructure and networks over which we have no direct control; (q) increases in license fees and our ability to obtain, maintain, renew or replace licenses, which may be suspended or revoked; (r) risks related to our ability to continue conducting our activities in a manner that does not cause us to be deemed an investment company under the Investment Company Act of 1940, as amended; (s) the loss of important intellectual property rights or third-party claims alleging infringement of intellectual property rights; (t) our substantial indebtedness and debt service obligations, which could materially decrease cash flow and adversely affect our business and financial condition; (u) our ability to maintain ownership and control of Worldcall Telecom Limited and 123 Investments Limited, as well as our status as a controlled company; (v) conflicts of interest; (w) our ability to comply with the extensive variety of laws and regulations applicable to our business and the uncertain judicial and regulatory environments in which we operate; (x) the fact that our operating subsidiaries, assets and certain of our officers and directors are located in Pakistan and the United Kingdom, which may affect shareholder rights, including the ability to enforce civil liabilities under U.S. securities laws; (y) the outcome of legal disputes, claims, investigations and litigation involving regulators, competitors and third parties; (z) risks relating to future divestitures, asset sales, joint ventures and acquisitions; (aa) the absence of an active trading market for our common stock and the risk that such a market may not develop or be sustained; (bb) future operating results; and (cc) other plans, objectives, expectations and intentions contained in this release that are not historical facts.

Other important factors that may cause actual results and outcomes to differ materially from those contained in the forward-looking statements included in this communication are described in Globaltech’s publicly filed reports, including, but not limited to, Globaltech’s Annual Report on Form 10-K for the year ended December 31, 2025, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, future Annual Reports on Form 10-K, and Quarterly Reports on Form 10-Q. These reports are available at www.sec.gov. Globaltech cautions that the foregoing list of important factors is not complete. All subsequent written and oral forward-looking statements attributable to Globaltech or any person acting on behalf of Globaltech are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on Globaltech’s future results. The forward-looking statements included in this press release are made only as of the date hereof. Globaltech cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Globaltech undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by Globaltech. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — Cambria Gold Mines Inc. (TSXV: CAMB; OTCQX: CAMVF) (“Cambria” or the “Company”) is pleased to provide a status update of ongoing construction, development, permitting, Feasibility Study preparation and infill drilling progress from the Premier Gold Project (“PGP” or the “Premier Project”) and Red Mountain Gold Project (“Red Mountain”), located near Stewart in northwestern British Columbia, as well as additions to its engineering and operational team. The Company is targeting commissioning of the 2,500 tonne per day mill at PGP in Q4 of 2027 with continued ramp up through 2028. Additionally, the Company is pleased to announce that over CA$45.9 million has been received through the exercise of outstanding warrants.

“Cambria continues to advance operational permitting, infill drilling, engineering and construction activities at PGP and Red Mountain, de-risking critical components to facilitate mining and processing in late 2027. Sufficient mineralization is accessible at PGP to commence mining, which would be subsequently augmented by Red Mountain once construction is complete,” said Robert McLeod, President and CEO of Cambria Gold Mines. “The Red Mountain Access Road construction is advancing very well and we are pushing to achieve access to Bromley Humps by the end of 2026.”

“As we complete additional development and prepare for operation readiness, our ability to attract exceptional engineers, such as: Ali Farah, Carla Romero, Brandon Chambers and Dinesh Devathasan, is driven by the quality of our gold projects and by our positive, supportive and determined team,” said Gord Doerksen, VP Projects of Cambria Gold Mines. “Our construction team has made strong headway in all facets, and our new engineering strength will set us up well for continued project development in 2027, with particular emphasis on planning and engineering, as well as water management and treatment and PGP.”

Red Mountain Access Road

The final Permit for the Red Mountain access road, a Fisheries Act Authorization (FAA), was received on September 21, 2026, allowing for in-stream construction work to be performed in Bitter Creek, rebuilding sections of a previous road that was washed away during a storm event in 2013.   With the FFA in hand, Cambria’s construction team and road building contractor are advancing the road expeditiously and safely toward our goal of reaching the Bromley Humps area near the base of Red Mountain, roughly 12 km from Highway 37A.

The alpine portion of the road to access the Red Mountain deposit is anticipated to be built during the 2027 construction season. The Company’s objective is to truck mill feed material to the mill at PGP, a distance of approximately 50 km, through the communities of Stewart and Hyder.

Additionally, the Company is studying bulk material transport options: an aerial tramline or rope conveyor from the Red Mountain Deposit to the Bitter Creek valley, which would be installed after the road is completed, likely following the first year of operations. These aerial conveyance systems have historically been used extensively in the region and modern systems have proven very successful globally.    

Figure 1. Red Mountain Access Road and Armouring adjacent to Bitter Creek

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4ccffa12-70de-46df-8bcc-d0da769e2743

Resource Modelling and Infill Drilling

To inform the updated Feasibility Study, the Company has built a comprehensive geological and assay database, remodelling the geology and mineralized zones of the PGP deposits with the purpose of informing an updated Mineral Resource and Reserve Estimate. The current Resource and Reserve Estimate, last updated in 2021, was modelled using grade shells rather than following geological units. Starting from first principles, Cambria’s geological team has been remodelling the major and peripheral deposits at PGP, integrating both new and historical data from over 100 years of mining history from multiple epithermal deposits.

Both the Big Missouri and Silver Coin Deposits, previously mined by Cominco and Westmin/Tenajon Resources were wide breccia and vein stockwork structures mined using longhole underground techniques. Cambria has modelled these structures as well as post mineral faults and dykes with the objective of outlining bulk mineable areas; infill drilling has been ongoing at both areas to increase confidence in grade and structure. Emphasis has been on the Silver Coin deposit, which has higher grades than Big Missouri, can be mined using productive longhole mining methods, and will be the primary focus for the restart along with the high-grade Premier deposit.

At the Premier Deposit, extensive infill drilling work on 12.5 metre spacing targeting high-grades within the Prew and 602 Zones has been prioritized. Once underground development has recommenced in Q4 2026, additional underground drilling will be completed to continue defining Measured Resources that could potentially convert to Proven Reserves and be accessed in the early years of the operation. This material would be blended with wide and continuous mineralization from Silver Coin and Big Missouri while the Red Mountain Deposit is developed.

Feasibility Study Update

Cambria continues to advance an updated Red Mountain-PGP Feasibility Study to capture the value of the combined project, with targeted completion in H1 2027. SLR Advisors, a global mining consultancy, has been engaged to be the primary author with support from QPs from other specialists in their respective fields.

As discussed in recent releases, the Feasibility Study work is informed by an extensive infill drilling program at PGP to provide robust resource confidence, as well as new metallurgical testing, mine plan optimization, and processing plant modifications to treat mineralized material from both projects. No additional infill drilling has been required at the Red Mountain Deposit.

Water Treatment Plant

At PGP, the priority work on the site has been water management and the water treatment plant. Since construction in 2024, the Water Treatment Plant (“WTP”) continually struggled with discharge compliance for zinc. Through a series of focused initiatives, expedited with urgency, the Company is advancing closer to compliance with results improving in the past two months. Extensive efforts have fixed many of the WTP’s operational problems, including taking over control of plant operations with in-house personnel (previously managed and operated by a contractor), engaging specialized water treatment consultants for guidance and activating better process controls. Cambria’s team completed extensive upgrades and additions to pumps, valves, pipes and various equipment that were in various stages of neglect. The Company also updated a water balance to better understand the entire water system and how best to manage and treat contact water.

Figure 2. New Upper Sediment Pond Liner at PGP Water Treatment Plant

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8f2b01b7-0e2e-4133-9893-946d7f267244

Mining

Cambria is currently upgrading underground infrastructure at Premier-Northern Lights with brow support, power upgrades, a ventilation bulkhead, water management sumps and secondary egress. These improvements will be complete by the end of 2026 and will allow us to begin additional development for stope access for mining and additional platforms for further infill drilling.  Underground work will be completed using Cambria’s newly purchased and commissioned fleet of mining equipment including LHDs, a twin-boom face jumbo, scissor deck and service vehicles. Additionally, underground development at the Silver Coin deposit will take place in the spring of 2027 to create development for operations. Accessing Silver Coin will be from the recently constructed underground workings at the Big Missouri deposit, 700 metres north of Silver Coin or from a new portal location closer to the mineralized zones, based on permitting considerations. Cambria’s remodelling of the Big Missouri Deposit has also identified the potential for several small open pit, that will be further evaluated as part of the Feasibility Study.

2026 geotechnical drilling at new Silver Coin and Red Mountain portal locations will assist in detailed portal design. All deposits benefit from previous underground development accelerating our development plan and reducing anticipated restart capital costs.

Premier Mill Upgrades

Detailed planning and budgeting of the Premier processing plant upgrades are underway with engineering, procurement and installation work. The mill operated as recently as 2025 and is in excellent condition. Based on past operating knowledge, the program includes some additional optimizations. These critical improvements include the installations of a new primary jaw crusher and feeder. The crusher building, covered crushed material stockpile and conveyor system, dating to the 1990’s operations are in excellent condition, with just the mechanical and electrical components required. Additional immediate upgrades will include converting an unused clarifier to a pre-leach thickener. Prior to introduction of material from Red Mountain, a fine grinding mill and second detox tank will be added. All required mill upgrades for restarting with Premier material will be completed in 2027.

Additions to Cambria’s Operating Team

To plan and execute on the Company’s re-start preparations, Cambria is pleased to announce the expansion of our project team with the addition of four exceptional people to the engineering team.

Ali Farah, P.Eng., a highly experienced Mechanical Engineer and Manager with over 35 years of experience, has joined Cambria as Director of Engineering responsible for all engineering activities for the Project. Ali will oversee all technical work done by consultants and in-house personnel to maintain high engineering standards, align all engineering work and ensure the greatest efficiency of design and execution. He will be a key piece of our strategic and tactical planning. Ali has a decade of experience in northwest BC mining in addition to +20-years of various technical and management roles in mining and other industries.  

Carla Romero Robiero, P.Eng. joined as Cambria’s Environmental Manager, with a primary focus on water system compliance, monitoring and reporting. Carla has 20 years of experience and was most recently the Senior Lead, Water Integrated Planning with a major mining company. She integrates water balance, water quality, treatment, mine planning, and financial analysis to guide assets toward resilient, low-risk outcomes.

Brandon Chambers, P.Eng. recently joined as our new Manager of Engineering. Brandon is a Mining Engineer with a broad range of operational, planning and construction experience. Brandon is an accomplished problem solver, planner and leader and will be extremely valuable providing guidance and knowledge to the wide range of initiatives Cambria is pursuing as well as providing engineering controls for our improvement plans.

Dinesh Devathasan, P.Eng. recently joined as our Underground Manager, who will lead Cambria’s team as underground development is advanced that takes the Company to production. Dinesh has proven, relevant experience in taking underground mining projects into successful, producing mines. Dinesh’s experience spans technical and management roles giving him the holistic knowledge needed to ensure a successful restart of Cambria’s mining assets. Dinesh has many years of Golden Triangle operating experience including at the Brucejack Mine.

Permitting

The Company achieved a significant permitting milestone in 2026 with the receipt of all permits required for construction of the Red Mountain access road. In parallel, Cambria is advancing engineering and environmental programs to support submission of the proposed haul road permit application. Baseline environmental studies were also conducted throughout 2026 at both the Premier and Red Mountain projects to validate and supplement existing environmental baseline information, while supporting ongoing project planning and future permitting requirements.

Looking ahead, the Company’s permitting efforts will focus on advancing the major mine authorizations required for the construction and operation of both the Premier and Red Mountain projects. At Red Mountain, ongoing engineering, environmental, and technical studies are also supporting an amendment to the existing Environmental Assessment Certificate to reflect the current project design and development plan. The Company continues to work collaboratively with regulatory agencies, Indigenous interests, and local stakeholders to advance these permitting processes.

Issuance of Interest Shares to Nebari

Further to the Company’s December 30, 2025 press release, and in connection with the second amended and restated facility agreement with Nebari Natural Resources Credit Fund II, LP and Nebari Gold Fund 1 LP, as lenders (the “Lenders”), and Nebari Collateral Agent LLC, as collateral agent (the “Collateral Agent”, and, together with the Lenders, “Nebari”) dated December 30, 2025 (the “Convertible Facilities”) and the third amended and restated cost overrun agreement entered into with Nebari dated December 30, 2025 (the “COF”), the Company intends to settle quarterly interest for the period beginning July 1, 2026 and ending September 30, 2026 of $1,800,253.06 payable to Nebari through the issuance of an aggregate of 2,017,318 common shares at a deemed price rounded to $0.892 per share, subject to approval of the TSX Venture Exchange. The interest has been calculated in accordance with the rates specified in the COF and Convertible Facilities.

All amounts are shown in Canadian dollars and Nebari is an arm’s length creditor to the Company.

Qualified Person and Technical Information:

The scientific and technical information within this news release was reviewed and approved by Gord Doerksen, P.Eng., Vice President of Projects for Cambria Gold Mines Inc. Mr. Doerksen is a non-independent “Qualified Person” as defined under National Instrument 43-101.

About Cambria Gold Mines

Cambria Gold Mines is a Canadian mining company headquartered in Vancouver, British Columbia, and its shares trade on the TSX-V under the ticker CAMB and on the OTCQX Market with the ticker CAMVF. Cambria is the 100% owner of the Premier Project and Red Mountain Gold Project that are located on Nisga’a Nation Treaty Lands, in the prolific Golden Triangle of northwestern British Columbia, as well as the large Mt. Margaret copper-gold porphyry deposit located in Washington State. For more information about the Company, please refer to the Company’s profile on SEDAR+ at www.sedarplus.ca or visit the Company’s web site at www.cambriagold.com.

On behalf of the Board of Directors of Cambria Gold Mines Inc.

Robert McLeod
CEO and Director 

For further information contact:

Email: info@cambriagold.com
Phone: 778-725-1060

and:

Sam Brezden
Email: sam.brezden@cambriagold.com
Phone: 236-838-1840

Or visit:

https://cambriagold.com/

Cautionary Statements:

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary Statement Regarding Forward-Looking Information
All statements and other information contained in this press release about anticipated future events may constitute forward-looking information under Canadian securities laws (“forward-looking statements”). Forward- looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeted”, “outlook”, “on track” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, “would” or “might” occur or be achieved and other similar expressions. All statements, other than statements of historical fact, included herein are forward-looking statements, including statements in respect of the targeted commissioning of the goals for the tonnes per day at PGP; the results and timing of the ramp up; the timing and completion of the access road construction; drill results resulting in actual increases of resources and reserves; the timing and certainty of the restart of the Premier mill and mining operations at the Premier and Red Mountain Projects; the timing and outcome of additional assay results; the timing and outcome of the updated Feasibility Study, the timing and completion of the Premier Mill upgrades; the receipt of the TSX Venture Exchange approval for the issuance of interest shares to Nebari; ability of the Company to accomplish its business objectives and the intentions described herein; and future plans, development and operations of the Company. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements; risks relating to negative operating cash flows of the Company; business and economic conditions in the mining industry generally; fluctuations in commodity prices and currency exchange rates; environmental compliance; risks related to outstanding debt; uncertainty of estimates and projections relating to development, production, costs and expenses, and health, safety and environmental risks; uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; the need to obtain additional financing to finance operations and uncertainty as to the availability and terms of future financing; social media and reputation; negative publicity; human rights; business objectives; shortage of personnel; health and safety; the possibility of delay in future plans and uncertainty of meeting anticipated program milestones; claims and legal proceedings; information systems and cyber security; internal controls; violation of anti-bribery or corruption laws; competition; tax considerations; compliance with listing standards; enforcement of civil liabilities; financing requirement risks; market price volatility of the common shares; uncertainty as to timely availability of permits and other governmental approvals; the need for exchange approval, and other regulatory approvals and other risk factors as detailed from time to time in Cambria’s filings with Canadian securities regulators, available on Cambria’s profile on SEDAR+ at www.sedarplus.ca including the Annual Management Discussion and Analysis of the Company for the year ended December 31, 2025 in the section entitled “Risk Factors”. Forward-looking statements are based on assumptions made with regard to: the estimated costs associated with the care and maintenance plans; the tax rate applicable to the Company; future commodity prices; the grade of mineral resources and mineral reserves; labor and materials costs increasing on a basis consistent with the Company’s current expectations, the ability of the Company to convert inferred mineral resources to other categories; the ability of the Company to reduce mining dilution; the ability to reduce capital costs; the ability of the Company to raise additional financing; currency exchange rates being approximately consistent with current levels, compliance with the covenants in Cambria’s credit agreements; exploration plans; and general marketing, political, business and economic conditions. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Although Cambria believes that the expectations reflected in such forward-looking statements and/or information are reasonable, undue reliance should not be placed on forward-looking statements since Cambria can give no assurance that such expectations will prove to be correct. Cambria does not undertake any obligation to update forward-looking statements, other than as required by applicable laws. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.

Tryg has compiled consensus estimates ahead of the Q3 2026 report. Consensus is based on input from 16 financial analysts.

Consensus is also available on tryg.com.

Attachment

• Q3 2026 – Consensus